Hovione and Bend agree manufacturing co-operation
To speed up delivery of medicines to market
Hovione, a Portuguese manufacturer of active pharmaceutical ingredients, has agreed a manufacturing co-operation with Bend Research in the US.
The collaboration will give clients of Bend Research, based in Bend, Oregon, US, access to Hovione’s commercial-scale pharmaceutical manufacturing facilities worldwide, while Hovione’s clients will have access to Bend Research’s oral drug-delivery, formulation, and engineering expertise.
‘We’re excited about this collaboration because Hovione will expand the range of manufacturing options available to our clients,’ said Rod Ray, chief executive of Bend Research.
In addition to manufacturing, the collaboration builds upon both companies’ expertise in many types of specialised formulations, including engineered particles for inhaled delivery.
Dave Hoffman, vp Exclusives and Particle Design at Hovione, said: ‘Hovione is very pleased to work collaboratively with Bend, a company with such extensive expertise in early and mid-stage development.
‘Leveraging on their capabilities, this collaboration will allow both companies to provide a comprehensive and integrated solution from development to commercial scale.’
The collaboration will allow technology transfer between the two firms, leveraging Bend Research’s clinical-trial-scale manufacturing facilities and scale-up and transfer expertise with Hovione’s wide range of capabilities, which includes cGMP manufacturing facilities in the US, Ireland, Portugal, and China.
